Abstracts tagged "pregnancy and systemic lupus erythematosus (SLE)"

Abstract Number: 1996 • 2015 ACR/ARHP Annual Meeting
Complement Activation Predicts Adverse Pregnancy Outcome in Patients with SLE and/or aPL Antibodies
Jane E. Salmon^1,2, Mimi Kim³, Marta Guerra⁴, Elianna Kaplowitz¹, Carl Laskin⁵, Michelle Petri⁶, Ware D. Branch^7,8, Michael Lockshin⁹, Lisa R. Sammaritano², Joan T. Merrill¹⁰, Mary D. Stephenson¹¹, Munther Khamashta¹², Alan M. Peaceman¹³, Anne Lynch¹⁴ and Jill P. Buyon¹⁵, ¹Hospital for Special Surgery, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Biostatistics and Research Design Resource, Albert Einstein Coll Med, Bronx, NY, ⁴Rheumatology 3rd Fl Rsrch, Hospital for Special Surgery, New York, NY, ⁵Medicine, Rheumatology and Obstetrics and Gynecology, University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷University of Utah, Salt Lake City, UT, ⁸Intermountain Healthcare, Salt Lake City, UT, ⁹Barbara Volcker Center for Women & Rheumatic Disease, Hospital for Special Surgery, New York, NY, ¹⁰Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹University of Illinois College of Medicine, Chicago, IL, ¹²Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ¹³Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁴Colorado School of Public Health, Aurora, CO, ¹⁵NYU School of Medicine, New York, NY
Background/Purpose: Women with SLE and/or aPL antibodies (SLE/APL) are at increased risk for adverse pregnancy outcomes (APO) yet identification of those destined for complications remains…
Abstract Number: 2120 • 2015 ACR/ARHP Annual Meeting
Alterations in Complement C3 and iC3b in SLE Pregnancies
Marta M. Guerra¹, Martin Schmidt², Elianna Kaplowitz³, Vibeke Strand⁴ and Jane E. Salmon⁵, ¹Rheumatology 3rd Fl Rsrch, Hospital for Special Surgery, New York, NY, ²Kypha, Inc., St. Louis, MO, ³Hospital for Special Surgery, New York, NY, ⁴Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, CA, ⁵Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: Pregnancy in patients with SLE is associated with increased risk of maternal and fetal complications. Studies in experimental models and humans suggest that complement…
Abstract Number: 2670 • 2014 ACR/ARHP Annual Meeting
Premature Delivery in Patients with Systemic Lupus Erythematosus
Valeria Arturi, Pierina Sansinanea, Mariana Alejandra Pera, Adrian Pablo Salas, Josefina Marcos, Ana Carolina Costi, Claudia Elizabeth Pena and Mercedes Argentina García, Rheumatology Unit, HIGA San Martín La Plata, La Plata, Argentina
Background/Purpose: Premature delivery (PD) is one of the most important difficultiess in perinatology. An incidence on developing countries of around 19% and 5-7% in developed…
Abstract Number: 2669 • 2014 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus and Lactation: Factors Affecting Infant Feeding Choices in Women with SLE
Sara Wasserman¹ and Megan E. B. Clowse², ¹Duke University Medical Center, Durham, NC, ²Rheumatology, Duke University Medical Center, Durham, NC
Background/Purpose: Breastfeeding has been shown to improve maternal and infant wellbeing and long-term health, but it is currently unknown how often it is pursued in…
Abstract Number: 2668 • 2014 ACR/ARHP Annual Meeting
Maternal Clinical Characteristics of SLE and Pregnancy: Hopkins Lupus Pregnancy Cohort
Michelle Petri¹, Amanda Eudy², Marcy Powell², Greg Giguere², Qinggong Fu² and Deanna Hill², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose Systemic lupus erythematosus (SLE) typically presents in women of childbearing age. As such, it is important to understand how the clinical characteristics of SLE…
Abstract Number: 2666 • 2014 ACR/ARHP Annual Meeting
Causes of Stillbirths in Women with SLE
Evelyne Vinet¹, Geneviève Genest², Susan Scott², Christian A. Pineau³, Ann E. Clarke⁴, Robert W. Platt⁵ and Sasha Bernatsky⁶, ¹McGill University Health Center, Montreal, QC, Canada, ²McGill University Health Centre, Montreal, QC, Canada, ³Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁴Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose It is believed that pregnant women with SLE face an increased risk of stillbirths, although there are few precise or recent estimates of the…
Abstract Number: 867 • 2014 ACR/ARHP Annual Meeting
Specific SLE Disease Manifestations in the Six Months Prior to Conception Predict Similar Manifestations during Pregnancy
Sara K. Tedeschi¹, Hongshu Guan¹, Alexander Fine¹, Bonnie L. Bermas² and Karen H. Costenbader², ¹Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Active SLE, in particular lupus nephritis, during the six months prior to conception is associated with disease flare during pregnancy. Previous studies, however, have…
Abstract Number: 2831 • 2013 ACR/ARHP Annual Meeting
Increased Risk Of Autism Spectrum Disorders In Children Born To Women With SLE: Preliminary Data From The O S L E R Cohort
Evelyne Vinet¹, Susan Scott², Christian A. Pineau³, Lawrence Joseph⁴, Ann E. Clarke⁵, Eric Fombonne⁶, Robert W. Platt⁴ and Sasha Bernatsky⁷, ¹McGill University Health Center, Montreal, QC, Canada, ²McGill University Health Centre, Montreal, QC, Canada, ³Rheumatology, McGill University Health Center, Montreal, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, ⁶Oregon Health and Sciences University, Portland, OR, ⁷Division of Clinical Epidemiology, McGill University Health Center, Montreal, QC, Canada
Background/Purpose: Recent experimental data suggest in utero exposure to maternal antibodies and cytokines as important risk factors for autism spectrum disorders (ASD). Interestingly, women with…
Abstract Number: 2833 • 2013 ACR/ARHP Annual Meeting
Increased Cardiac Septal Defects In Children Born To Women With Systemic Lupus Erythematosus: Results From The O S L E R Study
Evelyne Vinet¹, Susan Scott², Christian A. Pineau³, Ann E. Clarke⁴, Robert W. Platt⁴ and Sasha Bernatsky⁵, ¹McGill University Health Center, Montreal, QC, Canada, ²McGill University Health Centre, Montreal, QC, Canada, ³Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵Division of Clinical Epidemiology, McGill University Health Center, Montreal, QC, Canada
Background/Purpose: Cardiac septal defects, which include atrial septal defects (ASD) and ventricular septal defects (VSD), are the most frequent congenital heart anomalies in the general…
Abstract Number: 2552 • 2013 ACR/ARHP Annual Meeting
Predictive Significance Of ANTI-Prothrombin Antibodies For Second and Third Trimester Obstetric Complications In Patients With Systemic LUPUS Erythematosus and ANTI-Phospholipid Syndrome
Marta Mosca¹, Chiara Tani², Martina Fabris³, Francesca Strigini⁴, Linda Carli¹, Sabrina Vagnani⁵, Rosaria Talarico⁶, Chiara Baldini⁷, Alessandra Della Rossa⁸, Elio Tonutti⁹ and Stefano Bombardieri¹, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ³Institute of Clinical Pathology, Udine, Italy, ⁴University of Pisa, Pisa, Italy, ⁵Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁶Rheumatology Unit, Pisa, Italy, ⁷University of Pisa, Rheumatology Unit, Pisa, Italy, ⁸Clinical and Experimental Medicine, Rheumatology Unit, Pisa, Italy, ⁹Santa Maria Hospital, Udine, Italy
Background/Purpose: Anti-prothrombin antibodies (aPT) either alone or in association with other anti-phospholipid antibodies have been associated with an increased risk of thrombosis as well as…
Abstract Number: 2534 • 2013 ACR/ARHP Annual Meeting
Pregnancy Complications In Lupus: Retrospective Observational Analysis From a US Health Claims Database
Michelle. A. Petri¹, Paola Daly², Daphnee S. Pushparajah³, David Friesen⁴ and Lydia Makaroff³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Lupus Foundation of America, Washington DC, DC, ³UCB Pharma, Brussels, Belgium, ⁴UCB Pharma, Slough, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease most frequently affecting women of childbearing age. Women with SLE are known to be at…
Abstract Number: 2550 • 2013 ACR/ARHP Annual Meeting
Predictive Markers Of Preeclampsia During Pregnancy In Patients With Systemic Erithematosus LUPUS and / Or Antiphospholipid Syndrome
Esther Rodriguez-Almaraz¹, Elena Gonzalo-Gil², Ignacio Herráiz³, Paula I Gómez-Arriaga³, Paloma Vallejo³, Elena A López-Jiménez⁴, María Galindo Izquierdo¹ and Alberto Galindo Izquierdo³, ¹Department of Rheumatology. Hospital Universitario 12 de Octubre, Madrid, Spain, ²Grupo de Investigación en Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, ³Fetal Medicine Unit, Department of Obstetrics and Gynecology. Hospital Universitario 12 de Octubre., Madrid, Spain, ⁴Department of Biochemistry. Hospital Universitario 12 de Octubre., Madrid, Spain
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased risk of preeclampsia (PE), which can be confused with lupus nephritis. Our objective was to…
Abstract Number: 2513 • 2013 ACR/ARHP Annual Meeting
Anti-Mullerian Hormone In Patients With Systemic Lupus Erythematosus
Chiara Tani¹, Sabrina Vagnani², Linda Carli³, Giovanni Gallo⁴, Maria Rita Sessa⁵, Chiara Baldini⁶, Alessandra Della Rossa⁷, Rosaria Talarico⁸, Francesca Strigini³, Marco Maccheroni⁵, Stefano Bombardieri³ and Marta Mosca³, ¹Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ²Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ³Rheumatology Unit, University of Pisa, Pisa, Italy, ⁴Departement of Clinical and Experimental Medicine, Rheumatology Unit, Pisa, Italy, ⁵S. Chiara Hospital, Pisa, Italy, ⁶University of Pisa, Rheumatology Unit, Pisa, Italy, ⁷Clinical and Experimental Medicine, Rheumatology Unit, Pisa, Italy, ⁸Rheumatology Unit, Pisa, Italy
Background/Purpose: Systemic Lupus Erythematosus (SLE) frequently affects women in childbearing age; disease related factors and treatment can interfere with ovarian function. Anti-Mullerian-hormone (AMH) levels are…
Abstract Number: 2528 • 2013 ACR/ARHP Annual Meeting
Pregnancy Outcome In 69 Pregnancies Of Multinational Population In Qatar With Systemic Lupus Erythematosus
Abdul Razzakh Poil¹, Mohammed Hammoudeh¹, Prem Chandra², Abdo Lutf¹ and Samar AL Emadi^1,3, ¹Medicine/Rheumatology, Hamad General Hospital, Doha, Qatar, ²Medical Research Center, Hamad Medical Corporation, Doha, Qatar, ³Medicine, ASSISTANT proffesor of clinical medicine weill cornell medical school Qatar, Doha, Qatar
Background/Purpose: The aim of this study is to determine the frequencies of abnormal pregnancy outcomes in a cohort of patients in Qatar and to identify…
Abstract Number: 577 • 2013 ACR/ARHP Annual Meeting
Is An Excess Risk Of Attention Deficit Hyperactivity Disorder In Children Born To Women With SLE Mediated By In Utero Drug Exposures? Preliminary Data From The O S L E R Cohort
Evelyne Vinet¹, Susan Scott², Christian A. Pineau³, Lawrence Joseph⁴, Ann E. Clarke⁵, Eric Fombonne⁶, Robert W. Platt⁴ and Sasha Bernatsky⁷, ¹McGill University Health Center, Montreal, QC, Canada, ²McGill University Health Centre, Montreal, QC, Canada, ³Rheumatology, McGill University Health Center, Montreal, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, ⁶Oregon Health and Sciences University, Portland, OR, ⁷Clinical Epidemiology, Research Institute of the McGill University Health Ctre, Montreal, QC, Canada
Background/Purpose: Women with SLE display autoantibodies (e.g. anti-N-methyl-D-aspartate receptor antibodies) and cytokines (e.g. interleukin-6), which, in animal models, alter fetal brain development and induce behavioural…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].